Development — A Mab A Case Study In Bioprocess
The depth filters for the Protein A load are undersized by linear scale-up (based on volume). A more accurate scale-up factor——shows that the large-scale filter needs 2.5x more area than calculated. After revision, all filter capacity tests pass.
The case study concludes with a summary of key performance indicators (KPIs) for Mab-X:
A humanized IgG1 monoclonal antibody (mAb) targeting the immune checkpoint protein PD-L1, indicated for solid tumors. Challenge: The original lead candidate, produced in murine ascites, had low productivity (0.2 g/L) and high immunogenicity risk. The goal: develop a scalable, GMP-compliant process for Phase I clinical trials with a target titer >3 g/L and ≥95% purity.
68% from harvest to bulk drug substance. A Mab A Case Study In Bioprocess Development
[Target Product Profile (TPP)] │ ▼ [Quality Target Product Profile (QTPP)] │ ▼ [Critical Quality Attributes (CQAs)] │ ▼ [Design Space (Upstream & Downstream)] │ ▼ [Integrated Control Strategy] Foundations of the A-Mab Strategy 1. Defining the Quality Target Product Profile (QTPP)
Reached a peak upstream concentration of 5.8 g/L at the 500L scale, representing a 2.7-fold increase from baseline.
Evaluated for its ability to support high viable cell density (VCD) during the growth phase. The depth filters for the Protein A load
The downstream process utilized a standard three-column platform purification template, heavily optimized for this specific mAb's impurity profile.
A mAb Case Study in Bioprocess Development: Optimizing Yield, Quality, and Scalability
The journey starts by engineering the factory. A gene encoding the desired antibody is transfected into a stable host cell line, most commonly CHO cells, which are favored for their ability to perform human-like post-translational modifications and grow robustly in suspension culture. The goal of is to isolate a single, high-producing, and stable clone that can consistently deliver the required quantity and quality of the mAb. The case study concludes with a summary of
For subcutaneous delivery, the final drug product must be <2 mL volume. Mab-X is formulated at 150 mg/mL. Stability studies (4 weeks at 40°C) show that adding 0.02% polysorbate-80 prevents agitation-induced aggregation, but excess PS-80 causes visible particles. The optimized formulation is:
Out of 500 clones screened, Clone 17B shows the highest specific productivity (qP = 25 pg/cell/day). However, early batch cultures reveal a problematic metabolite profile: high lactate accumulation (4 g/L) and ammonia (2 mM). High lactate inhibits cell growth and reduces final titers.